People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management
Mineralys Therapeutics, Inc. has appointed Jessica Wagner Keliher, SPHR, as Vice President, Talent Management. Keliher brings over two decades of human resources leadership experience from the biotech and life sciences sectors, including previous roles at Cartesian Therapeutics, Novavax, and Kite Pharma. Her new role will focus on shaping the people and culture strategy as Mineralys Therapeutics prepares for the commercialization of its lead hypertension treatment, Lorundrostat.
Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS
The Timothy G. Youngquist 2020 Irrevocable Trust has acquired a new position in Mineralys Therapeutics, Inc. (MLYS) worth approximately $2.72 million, representing 0.12% of the company. Despite this institutional interest, the company recently reported a significant earnings miss, and while analysts have a consensus "Hold" rating with a $49.33 price target, insider selling has also occurred. Mineralys Therapeutics, headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and chronic kidney diseases.
TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS
TimesSquare Capital Management LLC has invested $6.36 million in Mineralys Therapeutics, Inc. by acquiring 235,858 shares, representing a 0.29% stake in the company. Despite significant institutional ownership (84.46%), insiders have recently sold shares, totaling $5.61 million. Mineralys Therapeutics reported a wider-than-expected quarterly loss of $2.85 per share, and analysts currently maintain a "Hold" rating with an average price target of $49.33.
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run
Mineralys Therapeutics, Inc. insider David Rodman has filed to sell 417 shares of common stock, valued at $10,616.82, through Merrill Lynch on August 17, 2026. This planned sale is related to the cashless exercise of employee stock options. The filing also reveals multiple prior significant sales by Rodman over the past three months, including transactions totaling over six figures in June, July, and August 2026.
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE
Bank of America Corp DE increased its stake in Mineralys Therapeutics (MLYS) by 11.5% in the first quarter, now owning 1.10 million shares valued at approximately $29.8 million. The company reported a significant second-quarter loss of $2.85 per share, substantially missing the expected $0.55 loss. Investors are also monitoring the December 22, 2026, PDUFA target date for its hypertension treatment, lorundrostat.
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"
Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share against a consensus of $0.55, and analysts expecting a full-year loss of $3.89 per share. However, Mineralys retains potential catalysts including a regulatory decision for its investigational hypertension treatment, lorundrostat, in December 2026, and sufficient funding into 2028.
Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen
Wall Street Zen downgraded Mineralys Therapeutics (NASDAQ:MLYS) to "Strong Sell" following a significant second-quarter earnings miss, where the company lost $2.85 per share against an expected $0.55 loss. Despite this, the broader analyst consensus remains a "Moderate Buy" with a $49.33 price target. Insider selling has also been noted, with executives selling approximately $5.6 million in stock over the past 90 days, while institutional investors hold 84.46% of the company.
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares
Mineralys Therapeutics insider David Rodman has filed a Form 144, indicating his intention to sell up to 14,056 shares of common stock through Merrill Lynch on or after August 13, 2026. The aggregate market value of the planned sale is $372,187.00. These shares originate from exercised employee stock options, including 7,707 shares via a cashless exercise and 6,349 shares for cash.
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced an inducement stock option award of 135,000 shares and a restricted stock unit award of 102,400 shares to Dr. Terry Ferguson, their new Chief Medical Officer. These awards, granted on August 10, 2026, are part of the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period, subject to continued service. The grants comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement for Dr. Ferguson's employment.
Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards
Mineralys Therapeutics (Nasdaq: MLYS) announced that its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson on August 10, 2026. These awards include a stock option for 135,000 shares and a restricted stock unit (RSU) award for 102,400 shares, both vesting over four years subject to continued service. The grants were made under the company's 2025 Employment Inducement Incentive Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced an inducement stock option award covering 135,000 shares and a restricted stock unit award covering 102,400 shares to Dr. Terry Ferguson, their new Chief Medical Officer. These awards, granted on August 10, 2026, are part of the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period, subject to Dr. Ferguson's continued service. The awards were made as a material inducement for his employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of common stock to Dr. Terry Ferguson, its newly appointed Chief Medical Officer. These awards, granted on August 10, 2026, were made under the company's 2025 Employment Inducement Incentive Award Plan and are subject to vesting schedules. The inducement is material to Dr. Ferguson's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback
Mineralys Therapeutics (MLYS) reported a wider Q2 2026 net loss of US$241.07 million, alongside confirming a December 22, 2026 PDUFA date for lorundrostat and repurchasing a royalty obligation. This update highlights the company's focus on regulatory progress and enhancing the long-term economics of its lead asset, while also sharpening concerns about cash burn and future financing needs. The company's recent financing package supports pre-launch activities but underscores increased losses and interest obligations as investors weigh approval upside against financial risks.
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,170 stock options for common stock at $16.00 per share and subsequently sold those 2,170 shares at $27.09 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in October 2025. Following these transactions, Rodman directly holds 13,024 stock options and 51,384 common shares.
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,170 shares for $58,785 and exercised stock options for an equal number of shares. These transactions were part of a Rule 10b5-1 trading plan. The company's shares show a significant annual return despite a year-to-date decline, and analysts maintain an optimistic outlook despite a recent wider-than-expected loss due to investment in a new blood pressure medication.
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock
Mineralys Therapeutics insider David Malcom Rodman sold 2,170 shares of the company's stock for $58,785.30, reducing his holdings by 4.05%. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, follows several other sales by Rodman in recent months. The company recently reported a significant second-quarter loss of $2.85 per share, missing analyst expectations, but maintains a "Moderate Buy" consensus rating from analysts with an average price target of $49.33, with a PDUFA target date for lorundrostat set for December 22, 2026.
Mineralys Therapeutics Q2 Earnings Call Highlights
Mineralys Therapeutics reported a wider second-quarter loss due to a $200 million payment for an amended agreement with Tanabe Pharma, but is progressing with commercial-launch preparations for lorundrostat ahead of its December PDUFA date. The company highlighted positive clinical data for lorundrostat in various patient populations and is actively building its commercial organization and engaging with payers for market access. Mineralys also secured significant financing through an equity offering and a term-loan facility to support its long-term strategy and commercialization efforts.
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.5, Implies 77% Upside
The average 12-month price target for Mineralys Therapeutics, Inc. (MLYS) stock has been slightly reduced from $49 to $48.5 by 8 analysts, with forecasts ranging from $30 to $56 per share. This new target suggests a potential upside of approximately 77% from the August 11 closing price. The consensus rating for MLYS among 9 analysts remains a "Buy."
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback
Mineralys Therapeutics reported a wider Q2 2026 net loss of US$241.07 million, alongside confirming a December 22, 2026 PDUFA target date for its lead asset, lorundrostat, and repurchasing a royalty obligation. This update highlights management's dual focus on regulatory progress and enhancing long-term economics, while the increased loss and royalty buyback sharpen concerns about cash burn and future financing. The company's investment narrative now centers on lorundrostat's FDA approval and commercialization potential versus the financial implications of ongoing losses and interest obligations.
Mineralys Therapeutics earnings up next as losses expected to widen
Mineralys Therapeutics is preparing to announce its second-quarter earnings, with analysts anticipating a widening of losses as the company advances its hypertension drug, lorundrostat, towards a potential FDA decision in December 2026. Despite the projected increase in losses, reflecting ongoing cash burn for commercialization, analysts maintain a bullish outlook on the stock. Investors will be closely watching for updates on the company's financial reserves and commercial preparation efforts.
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
Mineralys Therapeutics Inc (MLYS) reported its Q2 2026 earnings, highlighting a strong cash position of $661.4 million, sufficient to fund operations into 2028. Despite a significant net loss of $241.1 million due to a $200 million payment to Tanabe Pharma, the company shared positive clinical data for lorundrostat and detailed its commercial launch preparations, including payer engagement and sales force staffing ahead of its December PDUFA date. The article also covers Q&A highlights concerning financial outlook, FDA discussions, commercial strategy, and differentiation from competitors like AstraZeneca's baxdrostat.
Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest
Mineralys Therapeutics reported a widened net loss of $280.4 million for the first half of 2026, primarily due to a $200 million upfront R&D charge for a perpetual, royalty-free license for its hypertension candidate, lorundrostat. Despite the loss, the company strengthened its financial position to $661.4 million in cash and investments, supported by recent equity offerings and a new senior secured term loan facility. Management believes this funding will support planned operations, including a potential commercial launch of lorundrostat, for at least 12 months, with the FDA having accepted the NDA for lorundrostat with a PDUFA target date of December 22, 2026.
Mineralys Therapeutics falls 8% on second quarter EPS miss
Mineralys Therapeutics (NASDAQ:MLYS) reported a wider-than-expected second-quarter loss of $2.85 per share, missing analyst estimates of $2.63 per share. This loss was primarily due to a $200 million upfront payment to Tanabe and increased research and development, along with general and administrative expenses. Despite the financial miss, the company is preparing for the commercial launch of lorundrostat, pending FDA approval, and appointed a new Chief Medical Officer to lead these efforts.
Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced its second quarter 2026 financial results, highlighting progress in its clinical programs. The company provided an update on its corporate activities, focusing on key developments and future outlook. This release details the financial performance and strategic advancements made during the quarter.
Mineralys' Blood-Pressure Candidate Has Dec. 22 FDA Target Date
Mineralys Therapeutics reported its Q2 2026 financial results, including a $241 million net loss, and provided a corporate update on its aldosterone synthase inhibitor, lorundrostat. The FDA has set a PDUFA target date of December 22, 2026, for lorundrostat, and Mineralys is actively preparing for its commercial launch. The company also strengthened its financial position by amending its Tanabe license agreement, eliminating future royalties for an upfront payment and potential milestones, and appointed a new Chief Medical Officer, James J. “Terry” Ferguson III, M.D.
How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing
This article provides an AI-generated analysis of Mineralys Therapeutics Inc. (MLYS) focusing on its impact on rotational trading strategies. It highlights a positive near-term sentiment that may shift, a mid-channel oscillation pattern, and an exceptional risk-reward setup. The analysis includes institutional trading strategies for different risk profiles, multi-timeframe signal analysis, and key support and resistance levels.
How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing
Mineralys Therapeutics Inc. (MLYS) shows a positive near-term sentiment with a potential shift, indicating broader weak alignment within a mid-channel oscillation pattern. AI models suggest specific trading strategies for different risk profiles, highlighting a notable 109.0:1 risk-reward setup targeting a 29.4% gain versus 0.3% risk. Divergent sentiment across various time horizons implies choppy market conditions for MLYS.
Mineralys Therapeutics, Inc. Q2 2026: Net loss $(241.1)M, EPS $(2.85) — 10-Q Summary
Mineralys Therapeutics, Inc. reported a significant increase in its net loss for Q2 2026, reaching $(241.1)M, or $(2.85) per diluted share, compared to $(43.3)M in Q2 2025, with no product revenue generated to date. The company highlighted progress in its pipeline, including the NDA acceptance for lorundrostat with a PDUFA date set for December 22, 2026, and is scaling its pre-commercial organization in anticipation of a potential launch. Additionally, Mineralys amended its Tanabe license to a perpetual, royalty-free agreement, supporting future commercialization efforts.
MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings
MINERALYS THERAPEUTICS ($MLYS) reported its Q2 2026 earnings, missing analyst estimates with -$2.85 per share against an expected -$0.55, and revenue matching expectations at $0. Following the announcement, the stock price declined by 4.32%. The article also details significant insider trading activity, with 39 sales out of 41 trades in the past six months, and highlights major hedge fund movements in and out of MLYS stock.
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is preparing for the commercial launch of lorundrostat, pending FDA approval by the PDUFA target date of December 22, 2026, and has appointed Dr. Terry Ferguson as Chief Medical Officer. Mineralys also strengthened its balance sheet through strategic financing and repurchased the Tanabe royalty obligation to enhance lorundrostat's long-term economics.
Janus Henderson Group PLC Has $537,000 Stock Holdings in Mineralys Therapeutics, Inc. $MLYS
Janus Henderson Group PLC significantly reduced its stake in Mineralys Therapeutics, Inc. ($MLYS) by 98.4% in the first quarter, now holding 19,848 shares valued at $537,000. Despite this, institutional ownership remains high at 84.46%, with other major investors increasing their positions. The stock carries a "Moderate Buy" consensus rating from analysts, with an average price target of $49.33 against its current $27.38 share price.
Mineralys Therapeutics (MLYS) – David Rodman files Rule 144 for stock sale
David Rodman has filed a Rule 144 notice to sell 2,170 shares of Mineralys Therapeutics, Inc. common stock through Merrill Lynch on August 10, 2026. This planned sale is connected to the exercise of employee stock options via a cashless exercise. The filing also details several prior open-market sales of Mineralys common stock by Rodman over the past three months.
FMR LLC reports 5.1% Mineralys Therapeutics (MLYS) stake in amended ownership filing
FMR LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 5.1% in Mineralys Therapeutics, Inc. (MLYS), which accounts for 4,461,689.46 shares of common stock. The filing specifies that FMR LLC holds sole voting power over 4,461,164.00 shares and sole dispositive power over all 4,461,689.46 shares. Abigail P. Johnson also reports sole dispositive power over the same number of shares, but no voting power.
Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View
Mineralys Therapeutics (MLYS) is set to report its Q2 2026 earnings on August 11, 2026, with its stock currently seen as 47.9% undervalued by analysts, suggesting a fair value of $50.88 compared to its recent close of $26.50. This valuation hinges on the potential of its lead drug, lorundrostat, for uncontrolled and resistant hypertension, which could transition the company from R&D to revenue generation. However, the company faces risks related to approval timing and competition, despite long-term shareholder returns of nearly 100%.
Mineralys schedules live webcast for Aug. 11 Q2 update
Mineralys Therapeutics (Nasdaq: MLYS) announced it will report its second-quarter 2026 financial results after market close on Tuesday, August 11, 2026. The company will host a conference call and live webcast for investors and analysts at 4:30 p.m. ET on the same day to discuss the results. This announcement provides details for accessing the call and webcast, as well as an overview of the company's focus on developing medicines for hypertension and related conditions.
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
Mineralys Therapeutics will announce its financial results for the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026. The biopharmaceutical company will also host a conference call on the same day at 4:30 p.m. ET to discuss the results. Interested parties can access the call via phone or live webcast.
Mineralys Therapeutics to Announce Second Quarter 2026
Mineralys Therapeutics, Inc. announced it will report its financial results for the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results. Mineralys Therapeutics focuses on developing treatments for hypertension and aldosterone-related conditions.
Renaissance Technologies LLC Purchases 60,700 Shares of Mineralys Therapeutics, Inc. $MLYS
Renaissance Technologies LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 18.8% in the first quarter, acquiring an additional 60,700 shares to reach a total of 382,800 shares valued at approximately $10.37 million. Despite significant insider selling totaling over $6.2 million, analyst sentiment remains a "Moderate Buy" with an average price target significantly above the current trading price. Mineralys Therapeutics, a clinical-stage biopharmaceutical company, focuses on treatments for hypertension and chronic kidney diseases.
Certain Restricted Stock Units of Mineralys Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 3-AUG-2026.
Certain Restricted Stock Units of Mineralys Therapeutics, Inc. are under a lock-up agreement that will end on August 3, 2026. These units were locked up for 61 days, starting from June 3, 2026. This announcement highlights the conclusion of a restricted period for these specific financial instruments.
(MLYS) and the Role of Price-Sensitive Allocations
Mineralys Therapeutics Inc. (NASDAQ: MLYS) is showing weak sentiment across all time horizons, supporting a short bias. Quantitative Research Desk analysis indicates a mid-channel oscillation pattern and an exceptional 107.1:1 risk-reward short setup. The article provides detailed institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Mineralys Therapeutics Inc (MLYS) Institutional Confidence
This article from TradingKey focuses on the institutional confidence in Mineralys Therapeutics Inc (MLYS). It lists several major institutional shareholders and their shareholdings, highlighting changes in their positions. Key firms like Catalys Pacific, RA Capital Management, and Fidelity Management & Research Company LLC are noted, with Fidelity showing a significant increase in shares held.
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring an 80% Upside Potential in the Biotech Arena
Mineralys Therapeutics, Inc. (MLYS) is highlighted as a compelling biotech investment opportunity due to its focus on developing medicines for diseases like hypertension and chronic kidney disease, particularly its lead product lorundrostat. Analysts project an 80.08% upside potential, with 9 out of 10 ratings being a "buy." Despite current unprofitability reflective of its R&D phase, positive clinical trial results or regulatory approvals could significantly boost its stock.
New Mineralys hires receive stock awards vesting over four years
Mineralys Therapeutics granted inducement stock awards to two new non-executive employees, comprising stock options for 42,800 shares and restricted stock units for 32,100 shares. These awards, approved by the Compensation Committee on July 17 and July 20, 2026, are part of the company's 2025 Employment Inducement Incentive Award Plan and align with Nasdaq Listing Rule 5635(c)(4). Both the options and RSUs vest over a four-year period, contingent on continued service, with specific schedules for each type of award.
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Mineralys Therapeutics Inc (MLYS), providing a breakdown of major shareholders, their proportions, and evolving institutional holdings. It lists top individual institutional investors like Catalys Pacific, LLC and RA Capital Management, LP, and categorizes shareholder types such as investment advisors and venture capital. The piece also includes a historical overview of institutional shareholding changes and related ETF holdings for MLYS.
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Mineralys Therapeutics Inc (MLYS), though it notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows current stock information including the market cap and P/E TTM. The article indicates that more detailed financial analysis is unavailable at this time.
Mineralys Therapeutics Inc (MLYS) Cash Flow
This article presents the detailed quarterly and annual cash flow statements for Mineralys Therapeutics Inc (MLYS), covering operating, investing, and financing activities. It provides financial figures for various cash flow components from FY2021Q4 to FY2026Q1, along with year-over-year percentage changes. The article also includes a frequently asked questions (FAQs) section that defines different types of cash flow and highlights key figures for MLYS, such as operating cash flow, capital expenditures, and free cash flow.
Mineralys Therapeutics, Inc. Revenue Breakdown – NASDAQ:MLYS
This article provides a revenue breakdown for Mineralys Therapeutics, Inc. (MLYS) on NASDAQ, based on data from TradingView. It offers a general overview of the company's financial segment and performance metrics, but the core content of specific financial figures or detailed breakdowns appears to be missing or implied to be on a separate page.
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend history of Mineralys Therapeutics Inc (MLYS). It states that the company has distributed $0.00 in dividends over the past five years, indicating no recorded dividend payouts. The information includes the current stock price and market capitalization for MLYS.
Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common shares
Mineralys Therapeutics Chief Commercial Officer Eric Warren sold 7,438 shares on July 21, 2026, for $26.87 per share after exercising stock options. Following these transactions, his direct holdings decreased to 38,400 shares, with 245,438 stock options remaining outstanding. The total value disposed of was $199,900.
Form 4 Mineralys Therapeutics Inc For: 23 July By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Mineralys Therapeutics Inc. dated July 23. It indicates that the document is published by Reuters and includes the stock symbol MLYS, showing a slight negative performance of -1.07%. The main content of the article is simply the title of the filing.
